Analyst firms · H.C. Wainwright · SRPT

H.C. Wainwright SRPT price target and rating history

Sarepta Therapeutics Inc. (SRPT) · Health Care

H.C. Wainwright rates Sarepta Therapeutics Inc. (SRPT) Sell with a $5 price target, as of its latest action on Jul 29, 2025. It has published 4 rating actions on SRPT since November 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.

Current rating
Sell
Price target
$5
Median target, all firms
$23.50
Actions on SRPT
4

H.C. Wainwright price target on SRPT

$80$43$520252026
H.C. Wainwright price target on SRPT, each point a stated target, November 2024 to July 2025.

Every H.C. Wainwright rating on SRPT

How other firms rate SRPT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Deutsche BankHold$18Nov 10, 2026
Wolfe ResearchOutperform$27Jul 9, 2026
BarclaysEqual Weight$20Jan 28, 2026
WedbushOutperform$32Dec 9, 2025

Questions about H.C. Wainwright and SRPT

What is H.C. Wainwright's price target for SRPT?
H.C. Wainwright's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $5, from its action on Jul 29, 2025.
What is H.C. Wainwright's rating on SRPT?
H.C. Wainwright rates SRPT Sell, a bearish rating, as of Jul 29, 2025.
When did H.C. Wainwright last change its view on SRPT?
On Jul 29, 2025, H.C. Wainwright reiterates Sell, price target $5.
How does H.C. Wainwright's SRPT target compare with other analysts?
Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.

More SRPT rating histories

All H.C. Wainwright ratingsSRPT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.